Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dementia l: Introduction

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

Dementia

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ATTITUDE - Addressing attrition in longitudinal cancer cohorts: an in-depth qualitative analysis of experiences and perspectives on participation in longitudinal studies among breast cancer survivors.

Breast cancer research and treatment·2026

Same author

Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.

Lancet (London, England)·2025

Same author

Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study.

Breast cancer research : BCR·2025

Same author

Two-dimensional T2*-weighted multi-shot echo-planar imaging to detect cerebral microbleeds in neurocognitive disorders: A time-efficient alternative to susceptibility weighted angiography.

European journal of radiology·2025

Same author

Long-term behavioral symptom clusters among survivors of early-stage breast cancer: Development and validation of a predictive model.

Journal of the National Cancer Institute·2024

Same author

Cognition and Return to Work Status 2 Years After Breast Cancer Diagnosis.

JAMA network open·2024

Same journal

[Rehabilitation in the elderly subject with Parkinson's disease].

Psychologie & neuropsychiatrie du vieillissement·2013

Same journal

[Specificities of the treatment of Parkinson's disease in the elderly].

Psychologie & neuropsychiatrie du vieillissement·2013

Same journal

[Parkinson's disease dementia and Lewy body dementia].

Psychologie & neuropsychiatrie du vieillissement·2013

Same journal

[Cognitive disorders in Parkinson's disease without dementia].

Psychologie & neuropsychiatrie du vieillissement·2013

Same journal

[Psychotic symptoms in Parkinson's disease].

Psychologie & neuropsychiatrie du vieillissement·2013

Same journal

[Parkinson's disease: psychological and behavioral disorders].

Psychologie & neuropsychiatrie du vieillissement·2013

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

[Comorbidity and dementia].

Philippe Chassagne¹, Fatiha Idrissi-Kassimy, Olivier Rigal

¹Service de Médecine Interne Gériatrique, UPCOG, CHU de Rouen, France. philippe.chassagne@chu-rouen.fr

Psychologie & Neuropsychiatrie Du Vieillissement

|March 28, 2008

Summary

This summary is machine-generated.

Managing aging patients with dementia and comorbidities like cancer requires tailored care programs. Specific attention must be given to informed consent and treatment plans for high-risk therapies in these vulnerable individuals.

More Related Videos

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

Related Experiment Videos

Last Updated: Jul 6, 2026

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

Area of Science:

Gerontology
Neurology
Oncology

Context:

Epidemiological data link aging, dementia, and comorbidities (cancer, renal failure, undernourishment).
Chronic conditions complicate diagnosis and treatment in elderly patients with cognitive impairment.
Elderly individuals with dementia and severe diseases present unique management challenges.

Purpose:

To highlight the specific care programs needed for elderly patients with dementia and comorbidities.
To discuss the complexities of informed consent and treatment decisions for high-risk therapies in this population.
To outline the prognostic assessment and quality-of-life considerations for demented elderly patients facing severe illnesses.

Summary:

Management of elderly patients with dementia and comorbidities necessitates specialized care protocols.
Informed consent and detailed treatment explanations are crucial, especially for high-risk treatments like adjuvant chemotherapy.
Prognosis assessment and impact on autonomy and quality of life require careful consideration in demented patients.

Impact:

Ensures appropriate and ethical care for a vulnerable patient group.
Improves therapeutic management and patient-doctor communication.
Aids physicians and caregivers in developing effective, individualized care strategies.